| 1 | Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma | 11.0 | 21 | Citations (PDF) |
| 2 | Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma | 11.0 | 19 | Citations (PDF) |
| 3 | Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease | 15.0 | 56 | Citations (PDF) |
| 4 | MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages | 4.2 | 55 | Citations (PDF) |
| 5 | Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy | 4.5 | 51 | Citations (PDF) |
| 6 | Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols | 2.1 | 1 | Citations (PDF) |
| 7 | Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells | 2.1 | 2 | Citations (PDF) |
| 8 | MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes | 5.2 | 22 | Citations (PDF) |
| 9 | Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach | 4.7 | 2 | Citations (PDF) |
| 10 | Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers | 11.8 | 83 | Citations (PDF) |
| 11 | A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation | 2.7 | 11 | Citations (PDF) |
| 12 | Twist1 is required for the development of UVB-induced squamous cell carcinoma | 2.1 | 11 | Citations (PDF) |
| 13 | Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging | 17.8 | 76 | Citations (PDF) |
| 14 | The MYC oncogene — the grand orchestrator of cancer growth and immune evasion | 54.3 | 948 | Citations (PDF) |
| 15 | MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC | 3.9 | 34 | Citations (PDF) |
| 16 | MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies | 11.0 | 71 | Citations (PDF) |
| 17 | The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them | 0.6 | 110 | Citations (PDF) |
| 18 | Mitochondrial copper depletion suppresses triple-negative breast cancer in mice | 21.4 | 331 | Citations (PDF) |
| 19 | The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth | 21.2 | 190 | Citations (PDF) |
| 20 | MYC Regulates the HIF2α Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells | 4.2 | 96 | Citations (PDF) |
| 21 | Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression | 2.7 | 31 | Citations (PDF) |
| 22 | Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription | 4.8 | 140 | Citations (PDF) |
| 23 | A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma | 11.8 | 44 | Citations (PDF) |
| 24 | Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index | 2.7 | 19 | Citations (PDF) |
| 25 | O-GlcNAcylation is required for mutant <i>KRAS</i>-induced lung tumorigenesis | 6.8 | 80 | Citations (PDF) |
| 26 | The MYC oncogene is a global regulator of the immune response FreeBlood, 2018, 131, 2007-2015 | 5.3 | 236 | Citations (PDF) |
| 27 | Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma | 5.3 | 141 | Citations (PDF) |
| 28 | The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma | 5.2 | 350 | Citations (PDF) |
| 29 | MYC: Master Regulator of Immune Privilege | 8.4 | 100 | Citations (PDF) |
| 30 | Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma | 5.3 | 150 | Citations (PDF) |
| 31 | MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma | 11.0 | 81 | Citations (PDF) |
| 32 | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | 3.2 | 37 | Citations (PDF) |
| 33 | NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis | 31.8 | 740 | Citations (PDF) |
| 34 | KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study | 0.7 | 58 | Citations (PDF) |
| 35 | Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma ModelBlood, 2016, 128, 4172-4172 | 5.3 | 3 | Citations (PDF) |
| 36 | Metabolic vulnerabilities of MYC-induced cancer. | 0.5 | 14 | Citations (PDF) |
| 37 | BIM-mediated apoptosis and oncogene addiction.Aging, 2016, 8, 1834-1835 | 0.6 | 7 | Citations (PDF) |
| 38 | Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. | 2.2 | 302 | Citations (PDF) |
| 39 | The effect of environmental chemicals on the tumor microenvironment | 2.2 | 123 | Citations (PDF) |
| 40 | Cancer prevention and therapy through the modulation of the tumor microenvironment | 10.8 | 347 | Citations (PDF) |
| 41 | MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism | 5.3 | 254 | Citations (PDF) |
| 42 | MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells | 21.2 | 276 | Citations (PDF) |
| 43 | Designing a broad-spectrum integrative approach for cancer prevention and treatment | 10.8 | 271 | Citations (PDF) |
| 44 | Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis | 6.8 | 388 | Citations (PDF) |
| 45 | Activation of Cre Recombinase Alone Can Induce Complete Tumor Regression | 1.5 | 26 | Citations (PDF) |
| 46 | Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance | 5.3 | 16 | Citations (PDF) |
| 47 | MYC Activation Is a Hallmark of Cancer Initiation and Maintenance | 2.9 | 804 | Citations (PDF) |
| 48 | Oncogene withdrawal engages the immune system to induce sustained cancer regression | 5.3 | 23 | Citations (PDF) |
| 49 | Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance | 28.7 | 226 | Citations (PDF) |
| 50 | Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo | 16.8 | 468 | Citations (PDF) |
| 51 | An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation | 1.6 | 20 | Citations (PDF) |
| 52 | Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy | 7.3 | 143 | Citations (PDF) |
| 53 | MYC through miR-17-92 Suppresses Specific Target Genes to Maintain Survival, Autonomous Proliferation, and a Neoplastic State | 28.7 | 168 | Citations (PDF) |
| 54 | Alteration of the lipid profile in lymphomas induced by MYC overexpression | 5.3 | 134 | Citations (PDF) |
| 55 | Oncogene addiction: resetting the safety switch? | 0.5 | 6 | Citations (PDF) |
| 56 | Metabolic changes in cancer cells upon suppression of MYC | 3.2 | 59 | Citations (PDF) |
| 57 | Noncanonical roles of the immune system in eliciting oncogene addiction | 3.7 | 11 | Citations (PDF) |
| 58 | Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma | 7.4 | 173 | Citations (PDF) |
| 59 | CD271+ Bone Marrow Mesenchymal Stem Cells May Provide a Niche for Dormant Mycobacterium tuberculosis | 8.7 | 196 | Citations (PDF) |
| 60 | Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling | 5.3 | 37 | Citations (PDF) |
| 61 | A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide | 1.2 | 46 | Citations (PDF) |
| 62 | Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer Free | 4.2 | 82 | Citations (PDF) |
| 63 | Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis | 2.2 | 93 | Citations (PDF) |
| 64 | High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation†‡ | 4.2 | 61 | Citations (PDF) |
| 65 | HIF‐2α Suppresses p53 to Enhance the Stemness and Regenerative Potential of Human Embryonic Stem Cells | 2.7 | 74 | Citations (PDF) |
| 66 | Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. | 2.3 | 24 | Citations (PDF) |
| 67 | Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na | 0.7 | 60 | Citations (PDF) |
| 68 | STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma | 5.2 | 68 | Citations (PDF) |
| 69 | Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin’s lymphoma treated with PEP-C | 0.2 | 9 | Citations (PDF) |
| 70 | Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis | 6.8 | 73 | Citations (PDF) |
| 71 | SIRT1 and c-Myc Promote Liver Tumor Cell Survival and Predict Poor Survival of Human Hepatocellular Carcinomas | 1.5 | 127 | Citations (PDF) |
| 72 | Reactive Oxygen Species Regulate Nucleostemin Oligomerization and Protein Degradation* | 1.3 | 18 | Citations (PDF) |
| 73 | Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation | 8.7 | 41 | Citations (PDF) |
| 74 | Functional Interactions between Retinoblastoma and c-MYC in a Mouse Model of Hepatocellular Carcinoma | 1.5 | 14 | Citations (PDF) |
| 75 | Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction | 5.3 | 44 | Citations (PDF) |
| 76 | MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase | 4.2 | 181 | Citations (PDF) |
| 77 | CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation | 28.7 | 336 | Citations (PDF) |
| 78 | Development of a Micro-Computed Tomography–Based Image-Guided Conformal Radiotherapy System for Small Animals | 1.4 | 71 | Citations (PDF) |
| 79 | MYC as a regulator of ribosome biogenesis and protein synthesis | 34.1 | 960 | Citations (PDF) |
| 80 | Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics | 4.5 | 86 | Citations (PDF) |
| 81 | Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells | 4.2 | 25 | Citations (PDF) |
| 82 | MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell–Intrinsic and Host-Dependent Mechanisms | 1.9 | 122 | Citations (PDF) |
| 83 | PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide | 4.2 | 43 | Citations (PDF) |
| 84 | Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia FreeBlood, 2010, 115, 4061-4070 | 5.3 | 31 | Citations (PDF) |
| 85 | The interaction between Myc and Miz1 is required to antagonize TGFβ-dependent autocrine signaling during lymphoma formation and maintenance | 2.9 | 106 | Citations (PDF) |
| 86 | Noninvasive molecular imaging of c-Myc activation in living mice | 5.3 | 40 | Citations (PDF) |
| 87 | Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice | 6.0 | 39 | Citations (PDF) |
| 88 | Impact of Hydrodynamic Injection and phiC31 Integrase on Tumor Latency in a Mouse Model of MYC-Induced Hepatocellular Carcinoma | 1.5 | 18 | Citations (PDF) |
| 89 | Cell Cycle Re-Entry and Mitochondrial Defects in Myc-Mediated Hypertrophic Cardiomyopathy and Heart Failure | 1.5 | 51 | Citations (PDF) |
| 90 | Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage–response thresholds | 5.3 | 50 | Citations (PDF) |
| 91 | Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation† | 11.8 | 14 | Citations (PDF) |
| 92 | Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy | 0.9 | 34 | Citations (PDF) |
| 93 | Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy† | 11.8 | 511 | Citations (PDF) |
| 94 | SPECT and PET Imaging of EGF Receptors with Site-Specifically Labeled EGF and Dimeric EGF | 3.0 | 26 | Citations (PDF) |
| 95 | The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse | 2.8 | 95 | Citations (PDF) |
| 96 | Tumor dormancy and oncogene addiction Apmis, 2008, 116, 629-637 | 1.2 | 33 | Citations (PDF) |
| 97 | A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice | 23.2 | 13 | Citations (PDF) |
| 98 | Hepatotoxin-Induced Changes in the Adult Murine Liver Promote MYC-Induced Tumorigenesis | 1.5 | 40 | Citations (PDF) |
| 99 | Reversing Cancer From Inside and Out: Oncogene Addiction, Cellular Senescence, and the Angiogenic Switch | 0.9 | 19 | Citations (PDF) |
| 100 | Oncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit? | 4.2 | 93 | Citations (PDF) |
| 101 | 18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation | 3.2 | 15 | Citations (PDF) |
| 102 | Combined Analysis of Murine and Human Microarrays and ChIP Analysis Reveals Genes Associated with the Ability of MYC To Maintain Tumorigenesis | 2.2 | 87 | Citations (PDF) |
| 103 | Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas | 1.5 | 80 | Citations (PDF) |
| 104 | Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy | 3.2 | 21 | Citations (PDF) |
| 105 | Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis | 5.3 | 58 | Citations (PDF) |
| 106 | Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | 5.3 | 400 | Citations (PDF) |
| 107 | Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisBlood, 2007, 110, 2674-2684 | 5.3 | 62 | Citations (PDF) |
| 108 | HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo | 28.7 | 501 | Citations (PDF) |
| 109 | c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma | 2.9 | 827 | Citations (PDF) |
| 110 | Conditional transgenic models define how MYC initiates and maintains tumorigenesis | 10.8 | 136 | Citations (PDF) |
| 111 | Tumor Dormancy: Death and Resurrection of Cancer As Seen through Transgenic Mouse Models | 2.3 | 29 | Citations (PDF) |
| 112 | Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch | 5.3 | 151 | Citations (PDF) |
| 113 | Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model | 5.2 | 14 | Citations (PDF) |
| 114 | Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy | 4.2 | 101 | Citations (PDF) |
| 115 | Lethal Cutaneous Disease in Transgenic Mice Conditionally Expressing Type I Human T Cell Leukemia Virus Tax* | 1.3 | 60 | Citations (PDF) |
| 116 | Rehabilitation of cancer through oncogene inactivation | 8.5 | 30 | Citations (PDF) |
| 117 | Conditionally MYC:insights from novel transgenic models | 6.7 | 38 | Citations (PDF) |
| 118 | Reversible tumorigenesis | 3.2 | 9 | Citations (PDF) |
| 119 | The human BCL6 transgene promotes the development of lymphomas in the mouse | 5.3 | 75 | Citations (PDF) |
| 120 | The E47 transcription factor negatively regulates CD5 expression during thymocyte development | 5.3 | 21 | Citations (PDF) |
| 121 | Developmental Context Determines Latency of MYC-Induced Tumorigenesis | 3.1 | 133 | Citations (PDF) |
| 122 | MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer | 31.8 | 860 | Citations (PDF) |
| 123 | Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer | 10.8 | 58 | Citations (PDF) |
| 124 | Reversibility of oncogene-induced cancer | 2.4 | 72 | Citations (PDF) |
| 125 | Cancer revoked: oncogenes as therapeutic targets | 34.1 | 562 | Citations (PDF) |
| 126 | Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression | 5.3 | 155 | Citations (PDF) |
| 127 | How Cancers Escape Their Oncogene Habit | 2.3 | 23 | Citations (PDF) |
| 128 | Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocationsBlood, 2003, 101, 2797-2803 | 5.3 | 116 | Citations (PDF) |
| 129 | Pharmacological inactivation of MYC for the treatment of cancer. | 1.8 | 19 | Citations (PDF) |
| 130 | c-Myc Is a Critical Target for C/EBPα in Granulopoiesis | 1.5 | 245 | Citations (PDF) |
| 131 | Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts | 5.3 | 134 | Citations (PDF) |
| 132 | Transient excess of MYC activity can elicit genomic instability and tumorigenesis | 5.3 | 414 | Citations (PDF) |
| 133 | Reversible Tumorigenesis by MYC in Hematopoietic Lineages | 8.8 | 846 | Citations (PDF) |
| 134 | c-Myc, MHCI, and NK Resistance in Immunodeficiency Lymphomasa | 2.6 | 10 | Citations (PDF) |
| 135 | MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. | 1.0 | 67 | Citations (PDF) |
| 136 | Targeted O-GlcNAcylation enables functional rewiring of c-Myc. | 4.8 | 0 | Citations (PDF) |
